These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27632933)

  • 1. The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
    Somnay Y; Lubner S; Gill H; Matsumura JB; Chen H
    Cancer Gene Ther; 2016 Oct; 23(10):348-354. PubMed ID: 27632933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
    Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
    Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
    Liu X; Han EK; Anderson M; Shi Y; Semizarov D; Wang G; McGonigal T; Roberts L; Lasko L; Palma J; Zhu GD; Penning T; Rosenberg S; Giranda VL; Luo Y; Leverson J; Johnson EF; Shoemaker AR
    Mol Cancer Res; 2009 Oct; 7(10):1686-92. PubMed ID: 19825992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
    Liu X; Shi Y; Guan R; Donawho C; Luo Y; Palma J; Zhu GD; Johnson EF; Rodriguez LE; Ghoreishi-Haack N; Jarvis K; Hradil VP; Colon-Lopez M; Cox BF; Klinghofer V; Penning T; Rosenberg SH; Frost D; Giranda VL; Luo Y
    Mol Cancer Res; 2008 Oct; 6(10):1621-9. PubMed ID: 18922977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
    Palma JP; Rodriguez LE; Bontcheva-Diaz VD; Bouska JJ; Bukofzer G; Colon-Lopez M; Guan R; Jarvis K; Johnson EF; Klinghofer V; Liu X; Olson A; Saltarelli MJ; Shi Y; Stavropoulos JA; Zhu GD; Penning TD; Luo Y; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
    Anticancer Res; 2008; 28(5A):2625-35. PubMed ID: 19035287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
    Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
    Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.
    Siddharth S; Nayak D; Nayak A; Das S; Kundu CN
    DNA Repair (Amst); 2016 Sep; 45():44-55. PubMed ID: 27334689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
    Davidson D; Wang Y; Aloyz R; Panasci L
    Invest New Drugs; 2013 Apr; 31(2):461-8. PubMed ID: 23054213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.
    Somnay YR; Dull BZ; Eide J; Jaskula-Sztul R; Chen H
    Cancer Gene Ther; 2015 Oct; 22(10):496-505. PubMed ID: 26403073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
    Hsu HW; de Necochea-Campion R; Williams V; Duerksen-Hughes PJ; Simental AA; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jul; 50(7):662-9. PubMed ID: 24735547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
    Huehls AM; Wagner JM; Huntoon CJ; Geng L; Erlichman C; Patel AG; Kaufmann SH; Karnitz LM
    Cancer Res; 2011 Jul; 71(14):4944-54. PubMed ID: 21613406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
    Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
    Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
    Albert JM; Cao C; Kim KW; Willey CD; Geng L; Xiao D; Wang H; Sandler A; Johnson DH; Colevas AD; Low J; Rothenberg ML; Lu B
    Clin Cancer Res; 2007 May; 13(10):3033-42. PubMed ID: 17505006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
    Bowman KJ; White A; Golding BT; Griffin RJ; Curtin NJ
    Br J Cancer; 1998 Nov; 78(10):1269-77. PubMed ID: 9823965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p21CDKN1A participates in base excision repair by regulating the activity of poly(ADP-ribose) polymerase-1.
    Cazzalini O; Donà F; Savio M; Tillhon M; Maccario C; Perucca P; Stivala LA; Scovassi AI; Prosperi E
    DNA Repair (Amst); 2010 Jun; 9(6):627-35. PubMed ID: 20303835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells.
    Paul S; Chatterjee S; Sinha S; Dash SR; Pradhan R; Das B; Goutam K; Kundu CN
    Expert Opin Ther Targets; 2023; 27(10):999-1015. PubMed ID: 37787493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.